SCHEMBL13633852

SCHEMBL13633852

Cc1ccc2cccnc2c1NS(=O)(=O)c1cc(S(=O)(=O)c2ccccc2)cs1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 13/20 0.67
ALDH1A1 P00352 2/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
NFKBIA P25963 2/20 0.44
GLO1 Q04760 2/20 0.44
G6PD P11413 1/20 0.44
AGTR1 P30556 1/20 0.44
METAP2 P50579 1/20 0.44
METAP1 P53582 1/20 0.44
PAX8 Q06710 1/20 0.44
ATM Q13315 1/20 0.44
MMP2 P08253 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
RELA Q04206 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633916 0.86 SLC40A1 (0.72) SLC40A1ALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL13633850 0.84 SLC40A1 (0.65) SLC40A1ALDH1A1LMNAHTTTDP1
SCHEMBL11972869 0.81 SLC40A1 (1.00) SLC40A1ALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL13633855 0.77 NFKBIA (0.67) SLC40A1ALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL13633878 0.76 SLC40A1 (0.59) SLC40A1TDP1NFKBIAATMMEN1
SCHEMBL13633842 0.73 NFKBIA (0.68) SLC40A1ALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL13633824 0.73 SLC40A1 (0.68) SLC40A1ALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL13633768 0.73 SLC40A1 (0.61) SLC40A1ALDH1A1TDP1NFKBIAMEN1
SCHEMBL2055429 0.72 SLC40A1 (0.72) SLC40A1ALDH1A1LMNAHTTTDP1
SCHEMBL16509622 0.72 SMN1; SMN2 (0.46) ALDH1A1LMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A SLC40A1 4638/4885ALDH1A1 802/4885LMNA 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.